WSX2

WSX2 is a small molecule curcumin analog being developed by Canget BioTekpharma for the treatment of ovarian cancer, lung cancer, and colon cancer. As a synthetic derivative of curcumin, it is designed to improve upon the pharmacological limitations of natural curcumin, such as its low bioavailability and rapid metabolism, while potentially enhancing its anti-tumor efficacy. The drug is currently in the preclinical stage of development, with in vitro studies demonstrating activity against multiple cancer cell lines. While its specific molecular targets have not been publicly disclosed, curcumin analogs typically exert their effects by modulating various signaling pathways involved in cell growth, survival, and inflammation.